Beg M A, Ragland R
Postgrad Med J. 1979;55 Suppl 3:127-32.
The safety and efficacy of tienilic acid have been evaluated in studies of patients with mild to moderate essential hypertension, salt and water retention states and hyperuricaemia associated with gout. During the course of these studies 675 patients were treated with tienilic acid, 310 were treated with hydrochlorothiazide, 43 were treated with probenecid and 34 were treated with placebo. Overall, adverse reactions characterized as probably drug-related or questinably drug-related were reported in 28% of patients treated with tienilic acid, 24% treated with hydrochlorothiazide, 25% of patients treated with probenecid and 33% treated with placebo. The side effects encountered were mild in severity, reversible and represented extensions of the pharmacological activity of tienilic acid, hydrochlorothiazide and probenecid. These initial studies demonstrate that tienilic acid is safe and effective in the treatment of mild to moderate essential hypertension, salt and water retention states, including oedema associated with congestive cardiac failure or mild to moderate renal dysfunction, and in the management of elevated serum uric acid levels associated with gout.
在对轻度至中度原发性高血压、盐和水潴留状态以及与痛风相关的高尿酸血症患者的研究中，已对替尼酸的安全性和有效性进行了评估。在这些研究过程中，675例患者接受了替尼酸治疗，310例接受了氢氯噻嗪治疗，43例接受了丙磺舒治疗，34例接受了安慰剂治疗。总体而言，接受替尼酸治疗的患者中有28%报告了可能与药物相关或可疑与药物相关的不良反应，接受氢氯噻嗪治疗的患者中有24%，接受丙磺舒治疗的患者中有25%，接受安慰剂治疗的患者中有33%。所遇到的副作用严重程度较轻，可逆转，是替尼酸、氢氯噻嗪和丙磺舒药理活性的延伸。这些初步研究表明，替尼酸在治疗轻度至中度原发性高血压、盐和水潴留状态（包括与充血性心力衰竭或轻度至中度肾功能不全相关的水肿）以及管理与痛风相关的血清尿酸水平升高中是安全有效的。
